November 20, 2015
Press Release
SEKISUI CHEMICAL CO., LTD.
(TSE Code: 4204)
Notice of the Acquisition of Shares in the Clinical Diagnostic Reagents Company 'EIDIA Co. Ltd.'
SEKISUI CHEMICAL CO., LTD. (Headquarters: Osaka City, Osaka Prefecture; President: Teiji Koge; hereinafter called 'SEKISUI CHEMICAL') has signed a share transfer agreement with Eisai Co., Ltd. (Headquarters: Bunkyo-ku, Tokyo; Representative Corporate Officer and CEO: Haruo Naito; hereinafter called 'Eisai') today, to receive all of the shares thus far issued in the 100% Eisai subsidiary EIDIA Co., Ltd. (Headquarters: Chiyoda-ku, Tokyo; President: Atsushi Saito; hereinafter called 'EIDIA'), which manufactures, imports, and sells clinical diagnostic reagents, clinical analyzers, laboratory reagents, and physical and chemical equipment.
-
Background
SEKISUI CHEMICAL places its 'Diagnostic System' as one of its 'Growing 8' businesses that are driving growth throughout the Sekisui Chemical Group as part of the midterm management plan
'SHINKA!-Advance 2016' (FY2014 to FY2016) in which we are currently involved, and are pouring our efforts into expanding business in the Life Science fields, including the Diagnostic System business, centering on SEKISUI MEDICAL CO., LTD. (Headquarters: Chuo-ku, Tokyo; President and CEO: Hideo Tagashira; hereinafter called 'SEKISUI MEDICAL').
SEKISUI MEDICAL has hitherto configured a broad partnership with EIDIA from the joint development to the manufacture and sale of clinical diagnostic reagents.
The diagnostic reagents/ analyzers market size in Japan shows a stable trend of approx. 500 billion yen,
and in recent years this trend has increased slightly. Meanwhile, globally, the market is approx. 6 trillion yen, and there are prospects for market expansion concomitant with the economic growth of the emerging countries.
-
Reasons for Publishing the Shares Acquisition
The incorporation of EIDIA's specific technologies, products, and human resources into the Sekisui Chemical Group aims to grow the Sekisui Chemical Group's life science fields into a global business corpus with a real presence. Specifically, it is expected to manifest the following three effects in particular.
Expansion of the Scale and Content of the Diagnostics Business
Whereas SEKISUI MEDICAL focuses on diagnostics business such as 'hyperlipidemia', 'hematological disorders', 'diabetes', 'infectious diseases' and 'rheumatism', EIDIA's strengths lie in diagnostic reagents for 'cancer' and 'rheumatism'.
SEKISUI MEDICAL not only plans to expand the nature of its business by focusing anew on the 'cancer' diagnostics business, encouraged by the receipt of EIDIA shares, but also plans to further expand its business by reinforcing its product lineup by focusing on 'rheumatism', which is shared by both companies.
Sales Expansion through Reinforcement of Sales Links
SEKISUI CHEMICAL not only has manufacturing and sales bases for diagnostics businesses in America, Europe, and China through its consolidated subsidiary Sekisui Diagnostics, LLC. and SEKISUI MEDICAL TECHNOLOGY (CHINA) LTD., but also has sales companies that handle Sekisui Chemical Group products in each corner of the globe. After acquiring EIDIA, Sekisui Chemical group intends to expand sales of EIDIA's products through its sales routes both in Japan and other countries. In addition, EIDIA intends to maintain the sales collaboration with Eisai.
Reinforcement of R&D in New Areas
-
Summary of Subsidiary Company Being Transferred (EIDIA Co., Ltd.)
Name: EIDIA Co., Ltd.
Address: 1-10-6 Iwamoto-cho, Chiyoda-ku, Tokyo
Representative: President: Atsushi Saito
Principal Business: The manufacture, import, and sale of clinical diagnostic reagents, clinical analyzers, laboratory reagents, and physical and chemical equipment
Establishment: May 1954
Shareholder: Eisai Co., Ltd. 100%
Latest Business Results
Fiscal Year End
March 2013
March 2014
March 2015
Net Assets
12,636 million yen
12,975 million yen
13,321 million yen
Total Assets
15,449 million yen
15,604 million yen
16,244 million yen
Net Sales
6,188 million yen
6,252 million yen
6,285 million yen
Operating Income
519 million yen
554 million yen
585 million yen
Ordinary Income
558 million yen
585 million yen
616 million yen
Net Income
320 million yen
333 million yen
345 million yen
Website: http://www.eidia.co.jp/
-
Summary of Share Seller
Name: Eisai Co., Ltd.
Address: 4-6-10 Koishikawa, Bunkyo-ku, Tokyo
Representative: Representative Corporate Officer and CEO: Haruo Naito
Principal Business: R&D, manufacturing, sales, import, and export of pharmaceuticals
-
Assigned Price
22,450 million yen
-
Schedule
November 20, 2015: Share transfer agreement signed December 28, 2015: Scheduled date of share transfer
-
Impact on Business Results
The impact on the consolidated business results of SEKISUI CHEMICAL through the period of March 2016 is thought to be negligible, and there are no changes to the consolidated business results forecast announced on October 29,2015.
Consolidated Net Sales
Consolidated Operating Income
Consolidated Ordinary Income
Net Income Attributable to Shareholders
Consolidated Business Forecasts for the Period (To March 2016)
1,120,000
90,000
89,000
58,000
Consolidated Business Results for the Previous Period
(To March 2015)
1,112,748
85,764
87,978
52,995
Reference: Consolidated business forecast for the period (announced October 29,2015) and the previous period consolidated business results (unit: million yen)
- Addendum
Name: SEKISUI MEDICAL CO., LTD.
Address: KDX Nihombashi 313 Building, 13-5, Nihombashi 3-chome, Chuo-ku, Tokyo
Representative: President and CEO: Hideo Tagashira
Principal Business: Diagnostics Business, Pharmaceuticals & Fine Chemicals Business, ADME & Tox.
Research Business
Paid in Capital : 1.275 billion yen
Establishment: April 1, 2008 (previous incarnation as Daiichi Pure Chemicals Co., Ltd. established on July 10, 1947)
Shareholder: SEKISUI CHEMICAL CO., LTD. 100%
Sales: 36.7 billion yen (as of March 2015. SEKISUI MEDICAL alone)
Website: http://www.sekisuimedical.jp/
We will promote the prompt marketization of new products and the development of unique reagents through the mutual use of specific technologies unique to both SEKISUI MEDICAL and EIDIA.
Specifically, in addition to developing the diagnostic reagents in the key areas of 'cancer' and 'rheumatism', we will also pour our energies into the development of new biomarkers.
(5) Capital: ¥5,262,480,000
Approval of the relevant authorities is a condition for the transfer of these shares.
October 2006: Acquired Daiichi Pure Chemicals Co., Ltd. from Daiichi Pharmaceutical Co., Ltd. April 2008: SEKISUI CHEMICAL's medical business departments were merged with Daiichi Pure
Chemicals Co., Ltd., and the company name changed to SEKISUI MEDICAL CO., LTD.
distributed by |